
About LambdaVision
LambdaVision is a Healthcare company based in Farmington (United States) founded in 2009. Protein-based retinal prosthesis for degenerative eye diseases is provided. LambdaVision has raised $7.65 million across 10 funding rounds from investors including NASA, HHS and Boryung Pharmaceutical. The company has 7 employees. LambdaVision offers products and services including Protein-based Artificial Retina. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is LambdaVision, Inc. Its competitors include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals; 1 of its 3 listed competitors has raised funding.
Company details
LambdaVision was founded in 2009 in Farmington, United States, within the biotechnology sector focused on medical devices. A protein-based retinal prosthesis is developed by the company to address retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Photochemical properties of retinylidene proteins are utilized to enable high-resolution vision restoration. Operations center on improving patient quality of life through this innovative approach.
- Headquarters Farmington, United States
- Employees 7
- SectorsHealthcare
- Website lambdavision.com
- Social LinkedIn X Facebook
- Legal Name Lambdavision, Inc
- Total Equity Funding$7.65M (USD)
in 10 rounds
- Latest Funding Round$7M (USD), Seed
Nov 2025
- InvestorsNASA
& 8 more
- Employee Count7
Products & Services of LambdaVision
LambdaVision offers a comprehensive portfolio of products and services, including Protein-based Artificial Retina.
Restores vision by mimicking photoreceptors in retinal diseases.
Funding Insights of LambdaVision
LambdaVision has successfully raised a total of $7.65M across 10 strategic funding rounds. The most recent funding activity was a Seed round of $7 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.65M
- Total Rounds 10
- Last Round Seed — $7M
- First Round $40,000
(Oct 2011)
- Investors Count 9
All 10 funding rounds of LambdaVision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $7M | Seed | – | Seven Seven Six | – |
| May 2024 | Series A | – | Aurelia Foundry | ||
| Sep 2020 | Grant | – | – | ||
| Oct 2017 | $500,000 | Series A | – | – | |
| Nov 2016 | Grant | – | – | ||
| Sep 2016 | $1.04M | Grant | – | – | |
| Jan 2015 | $179,937 | Grant | – | – | |
| Sep 2014 | $170,662 | Grant | – | – | |
| May 2013 | $110,000 | Seed | – | – | |
| Oct 2011 | $40,000 | Seed | – | – |
9 investors in total: 9 institutional.
Investors in LambdaVision
LambdaVision has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NASA, HHS and Boryung Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in tech sectors | e2mc.space | Orlando, United States | ||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Venture capital fund focused on investing in technology startups | sevensevensix.com | |||
Finished formulations and APIs are developed for diverse disease areas. | 1963 | boryung.co.kr | Seoul, South Korea | |
Invests in and incubates startups focused on space, AI, and climate technologies. | 2023 | aureliafoundry.com | Wellesley, United States | |
Government space exploration and research services are provided. | 1958 | nasa.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for LambdaVision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LambdaVision
7 people are tracked at LambdaVision (3 in leadership, 4 in board & advisors); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Nicole L. Wagner | President & CEO | Leadership |
Jordan A. Greco | Chief Scientific Officer | Leadership |
Jordan Greco, Ph.D. | Chief Scientific Officer | Leadership |
Susan Froshauer | Director | Board & advisors |
Robert R. Birge | Founder | Board & advisors |
Pauline Murphy | Director | Board & advisors |
Kirk Dornbush | Director | Board & advisors |
Complete people profiles for LambdaVision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of LambdaVision
3 dated milestones of LambdaVision across 16 years, from founding to its latest funding, stage changes and deals.
- Founded LambdaVision is founded.
- Funding First funding round of $40K.
- Funding Latest funding round, Seed, of $7.0M.
Competitors of LambdaVision
LambdaVision has 3 listed competitors in our database, 1 of them funded. They include Rezolute, Aviceda Therapeutics and EyePoint Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | ||
| avicedarx.com | 2018 | Cambridge, United States | $254.66M | Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. | ||
| eyepointpharma.com | 1987 | Watertown, United States | 49 | Small molecule therapeutics for ophthalmic disorders are developed. |
Detailed competitors of LambdaVision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of LambdaVision
The website of LambdaVision (lambdavision.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 2.5% vs previous month
Websites whose visitors overlap most with LambdaVision. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details |
Top companies in Ophthalmology
3 companies that operate in the same segment as LambdaVision (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lambdavision
Complete news archive for LambdaVision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LambdaVision
LambdaVision was founded in 2009 and raised its 1st funding round 2 years after it was founded.
LambdaVision is headquartered in Farmington, United States.
LambdaVision is a funded company, having raised a total of $7.65M across 10 funding rounds to date. The company's 1st funding round was a Seed of $40K, raised on Oct 2011.
LambdaVision has 7 employees.
LambdaVision was founded in 2009 in Farmington, United States, within the biotechnology sector focused on medical devices. A protein-based retinal prosthesis is developed by the company to address retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Photochemical properties of retinylidene proteins are utilized to enable high-resolution vision restoration. Operations center on improving patient quality of life through this innovative approach.
LambdaVision's top competitors include EyePoint Pharmaceuticals, Rezolute and Aviceda Therapeutics.
LambdaVision offers Protein-based Artificial Retina.
LambdaVision has 9 investors. Key investors include NASA, HHS, Boryung Pharmaceutical, E2MC, and Aurelia Foundry.
LambdaVision operates through Lambdavision, Inc.
